Home Medicine Chapter 3 Combating chronic obstructive pulmonary disease (COPD) using nanocarriers
Chapter
Licensed
Unlicensed Requires Authentication

Chapter 3 Combating chronic obstructive pulmonary disease (COPD) using nanocarriers

  • Surbhi Sharma , Garima Rai , Harshit Devtalla , Pammi Gauba and Shweta Dang
Become an author with De Gruyter Brill
Explore this Subject How to publish with us
Nanocarrier Drug Delivery Systems
This chapter is in the book Nanocarrier Drug Delivery Systems

Abstract

A chronic respiratory condition known as chronic obstructive pulmonary disease (COPD) is represented by continuous obstructions in airflow and lung inflammation. Major causes of COPD include air pollution, extended exposure to irritant chemicals and particles such as cigarette smoke, and hazardous waste released from factories. Chronic bronchitis and emphysema are the two main disorders that constitute COPD. Dyspnea, wheezing, chest tightness, a persistent cough (with or without sputum production), and weariness are all typical symptoms of COPD. These symptoms greatly impact everyday activities and quality of life, which tend to worsen over time. The current therapy regimen for COPD seeks to relieve symptoms, improve lung function, and decrease the frequency and severity of exacerbations. The treatment option includes bronchodilators such as β-agonists and anticholinergics, PDE-4 inhibitors, inhaled corticosteroids, antioxidant therapy, antibiotics, and antivirals. Due to their distinct properties and biocompatibility profile, novel drug delivery carriers can be used in COPD based on the material used for the development and modification of the surface. Therapeutic drugs can be delivered directly to the lungs using nanocarriers such as liposomes, polymeric nanoparticles, and solid lipid nanoparticles, offering tailored treatment and reducing systemic side effects. The selectivity and absorption of nanocarriers can be improved by functionalizing them with ligands or antibodies that are specific to receptors overexpressed in COPD. Nanocarriers can be used to regulate and sustain drug release over an extended period. This sustained release profile raises treatment compliance and lowers medication administration frequency. Various clinical trials have been performed to estimate the safety and efficacy of new medications or treatment strategies for COPD, among which some studies have also been discussed in the chapter.

Abstract

A chronic respiratory condition known as chronic obstructive pulmonary disease (COPD) is represented by continuous obstructions in airflow and lung inflammation. Major causes of COPD include air pollution, extended exposure to irritant chemicals and particles such as cigarette smoke, and hazardous waste released from factories. Chronic bronchitis and emphysema are the two main disorders that constitute COPD. Dyspnea, wheezing, chest tightness, a persistent cough (with or without sputum production), and weariness are all typical symptoms of COPD. These symptoms greatly impact everyday activities and quality of life, which tend to worsen over time. The current therapy regimen for COPD seeks to relieve symptoms, improve lung function, and decrease the frequency and severity of exacerbations. The treatment option includes bronchodilators such as β-agonists and anticholinergics, PDE-4 inhibitors, inhaled corticosteroids, antioxidant therapy, antibiotics, and antivirals. Due to their distinct properties and biocompatibility profile, novel drug delivery carriers can be used in COPD based on the material used for the development and modification of the surface. Therapeutic drugs can be delivered directly to the lungs using nanocarriers such as liposomes, polymeric nanoparticles, and solid lipid nanoparticles, offering tailored treatment and reducing systemic side effects. The selectivity and absorption of nanocarriers can be improved by functionalizing them with ligands or antibodies that are specific to receptors overexpressed in COPD. Nanocarriers can be used to regulate and sustain drug release over an extended period. This sustained release profile raises treatment compliance and lowers medication administration frequency. Various clinical trials have been performed to estimate the safety and efficacy of new medications or treatment strategies for COPD, among which some studies have also been discussed in the chapter.

Chapters in this book

  1. Frontmatter I
  2. Contents V
  3. List of contributors IX
  4. Chapter 1 Nanocarrier drug delivery System: recent advancement and future potential 1
  5. Chapter 2 Nanocarriers for disease chasing and management 31
  6. Chapter 3 Combating chronic obstructive pulmonary disease (COPD) using nanocarriers 57
  7. Chapter 4 Neurological disease management with nanoparticles 85
  8. Chapter 5 Nanocarriers in cardiovascular diseases 125
  9. Chapter 6 Nanocarrier-based methods for effective antitubercular drug delivery 161
  10. Chapter 7 Nanocarriers in fungal drug delivery system 185
  11. Chapter 8 Nanocarriers in management of breast cancer 213
  12. Chapter 9 Nanocarriers in ulcerative colitis 247
  13. Chapter 10 Advancement of nanocarrier-based drug delivery system for Chagas disease 277
  14. Chapter 11 Topical drug delivery for psoriasis using nanocarriers 307
  15. Chapter 12 Dermopharmaceutical formulations based on nanocarriers for the topical treatment of atopic dermatitis 355
  16. Chapter 13 Nanocarriers in transdermal drug delivery 387
  17. Chapter 14 Bioactive-loaded nanocarriers in management of health and disease 419
  18. Chapter 15 Nanocarriers for ocular drug delivery 469
  19. Chapter 16 Nanocarriers for the management of Alzheimer’s disease 501
  20. Chapter 17 Nanocarriers in combined medication delivery: issues and prospects 533
  21. Chapter 18 Nanocarriers for antimicrobial therapy 561
  22. Chapter 19 Nanocarriers for treatment of Parkinson’s disease 603
  23. Index 637
https://doi.org/10.1515/9783111320847-003

Chapters in this book

  1. Frontmatter I
  2. Contents V
  3. List of contributors IX
  4. Chapter 1 Nanocarrier drug delivery System: recent advancement and future potential 1
  5. Chapter 2 Nanocarriers for disease chasing and management 31
  6. Chapter 3 Combating chronic obstructive pulmonary disease (COPD) using nanocarriers 57
  7. Chapter 4 Neurological disease management with nanoparticles 85
  8. Chapter 5 Nanocarriers in cardiovascular diseases 125
  9. Chapter 6 Nanocarrier-based methods for effective antitubercular drug delivery 161
  10. Chapter 7 Nanocarriers in fungal drug delivery system 185
  11. Chapter 8 Nanocarriers in management of breast cancer 213
  12. Chapter 9 Nanocarriers in ulcerative colitis 247
  13. Chapter 10 Advancement of nanocarrier-based drug delivery system for Chagas disease 277
  14. Chapter 11 Topical drug delivery for psoriasis using nanocarriers 307
  15. Chapter 12 Dermopharmaceutical formulations based on nanocarriers for the topical treatment of atopic dermatitis 355
  16. Chapter 13 Nanocarriers in transdermal drug delivery 387
  17. Chapter 14 Bioactive-loaded nanocarriers in management of health and disease 419
  18. Chapter 15 Nanocarriers for ocular drug delivery 469
  19. Chapter 16 Nanocarriers for the management of Alzheimer’s disease 501
  20. Chapter 17 Nanocarriers in combined medication delivery: issues and prospects 533
  21. Chapter 18 Nanocarriers for antimicrobial therapy 561
  22. Chapter 19 Nanocarriers for treatment of Parkinson’s disease 603
  23. Index 637
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 15.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/9783111320847-003/pdf?licenseType=restricted
Scroll to top button